From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Cardiology>
  4. Summary and Comment

Vasodilators Tested in Asymptomatic Aortic Regurgitation

In patients with asymptomatic, chronic, severe aortic regurgitation, vasodilator treatment neither reduced nor delayed the need for aortic valve replacement.

ACC/AHA guidelines on valvular heart disease strongly recommend vasodilator therapy for patients with symptomatic or asymptomatic severe aortic regurgitation, left-ventricular dilation, and normal LV systolic function. However, the evidence in asymptomatic patients is not solid. Researchers in Spain conducted a randomized, open-label trial comparing nifedipine (20 mg every 12 hours), enalapril (20 mg daily), or no treatment in 95 patients with asymptomatic, chronic, severe aortic regurgitation (mean age, 43; 78% men; mean LV ejection fraction, 59%; mean LV end-diastolic dimension, about 6.6 cm).

Aortic valve replacement (AVR) was performed, according to an explicit protocol, only for symptoms or for LV dysfunction or enlargement. During a mean follow-up of 7 years, the need for AVR did not differ significantly among the groups (41% of the nifedipine group, 50% of the enalapril group, and 39% of the no-treatment group), nor did the mean time elapsed until AVR (5.4, 4.2, and 5.4 years, respectively). Changes in echocardiographic measures also were similar among the groups. No patients died from surgery.

Comment: In patients with asymptomatic, chronic, severe aortic regurgitation, vasodilator treatment (with nifedipine or enalapril) neither reduced nor delayed the need for aortic valve replacement. Although the study was small, its findings nonetheless cast doubt upon the current guideline recommendation. What’s clear, as an editorialist notes, is the paucity of trial findings to guide the care of patients with significant valvular disease.

— Harlan M. Krumholz, MD, SM

Published in Journal Watch Cardiology October 21, 2005

Citation(s):

Evangelista A et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005 Sep 29; 353:1342-9.

Carabello BA. Vasodilators in aortic regurgitation — Where is the evidence of their effectiveness? N Engl J Med 2005 Sep 29; 353:1400-2.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2005. Massachusetts Medical Society. All rights reserved.